Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Pharma Industry Analysis

UpdatedMay 13, 2025
DataAggregated Company Financials
Companies300
  • 7D-3.8%
  • 3M-8.4%
  • 1Y-7.4%
  • YTD-4.6%

Over the last 7 days, the Pharma industry has dropped 3.8%, driven by a pullback from Eli Lilly of 8.0%. On the other hand Regencell Bioscience Holdings is actually up 406%. Overall the industry is down 7.4% in 12 months. As for the next few years, earnings are expected to grow by 14% per annum.

Industry Valuation and Performance

Has the U.S. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 13 May 2025US$1.7tUS$382.6bUS$61.0b17.1x27.1x4.3x
Thu, 10 Apr 2025US$1.6tUS$379.9bUS$40.6b16.1x40.1x4.3x
Sat, 08 Mar 2025US$2.0tUS$381.1bUS$39.2b16.5x49.8x5.1x
Mon, 03 Feb 2025US$1.9tUS$370.4bUS$29.8b18.4x62x5x
Wed, 01 Jan 2025US$1.8tUS$369.3bUS$31.3b16.5x56.9x4.8x
Fri, 29 Nov 2024US$1.9tUS$373.8bUS$30.6b19.8x60.9x5x
Sun, 27 Oct 2024US$2.0tUS$365.3bUS$23.7b17.9x83.2x5.4x
Tue, 24 Sep 2024US$2.0tUS$364.2bUS$25.3b18.9x80.4x5.6x
Thu, 22 Aug 2024US$2.0tUS$362.1bUS$21.8b18x93.3x5.6x
Sat, 20 Jul 2024US$1.9tUS$356.5bUS$13.1b15.9x148.2x5.4x
Mon, 17 Jun 2024US$1.9tUS$358.3bUS$14.1b15.3x137.4x5.4x
Wed, 15 May 2024US$1.9tUS$358.2bUS$13.8b18.1x134.6x5.2x
Fri, 12 Apr 2024US$1.8tUS$355.1bUS$23.9b23.4x76.9x5.2x
Sun, 10 Mar 2024US$1.9tUS$355.3bUS$22.4b22.5x84x5.3x
Tue, 06 Feb 2024US$1.8tUS$352.8bUS$22.8b28.1x79.4x5.1x
Thu, 04 Jan 2024US$1.8tUS$375.2bUS$33.8b27.7x51.7x4.7x
Sat, 02 Dec 2023US$1.7tUS$375.2bUS$33.9b27.2x48.6x4.4x
Mon, 30 Oct 2023US$1.6tUS$383.5bUS$46.6b14.2x34.1x4.1x
Wed, 27 Sep 2023US$1.7tUS$381.8bUS$43.9b18.5x38.1x4.4x
Fri, 25 Aug 2023US$1.8tUS$381.6bUS$44.1b19.8x39.9x4.6x
Sun, 23 Jul 2023US$1.7tUS$394.3bUS$60.5b18.6x28.7x4.4x
Tue, 20 Jun 2023US$1.7tUS$392.8bUS$60.1b19x29x4.4x
Thu, 18 May 2023US$1.7tUS$393.1bUS$60.5b18.7x28.4x4.4x
Sat, 15 Apr 2023US$1.7tUS$401.3bUS$68.5b17.5x24.3x4.2x
Mon, 13 Mar 2023US$1.5tUS$401.1bUS$69.5b17.4x21.9x3.8x
Wed, 08 Feb 2023US$1.7tUS$402.0bUS$69.9b18.4x23.8x4.1x
Fri, 06 Jan 2023US$1.7tUS$403.7bUS$70.7b17.2x24.7x4.3x
Sun, 04 Dec 2022US$1.8tUS$403.7bUS$70.7b17.2x25.3x4.4x
Tue, 01 Nov 2022US$1.7tUS$404.8bUS$70.8b16.1x24.1x4.2x
Thu, 29 Sep 2022US$1.6tUS$403.0bUS$71.3b12.6x22.3x3.9x
Sat, 27 Aug 2022US$1.6tUS$402.9bUS$70.2b14.7x22.9x4x
Mon, 25 Jul 2022US$1.7tUS$393.1bUS$63.6b22.2x26.1x4.2x
Wed, 22 Jun 2022US$1.6tUS$392.5bUS$64.7b21.3x24.8x4.1x
Fri, 20 May 2022US$1.6tUS$392.5bUS$64.6b20x25.5x4.2x
Price to Earnings Ratio

25.5x


Total Market Cap: US$1.6tTotal Earnings: US$64.6bTotal Revenue: US$392.5bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Pharma Industry Price to Earnings3Y Average 51.9x202320242025
Current Industry PE
  • Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 27.1x which is lower than its 3-year average PE of 51.9x.
  • The industry is trading close to its 3-year average PS ratio of 4.6x.
Past Earnings Growth
  • Both revenue and earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
  • This means that sales and the cost of doing business have remained relatively consistent over this period and subsequently, so have profits.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market3.92%
Healthcare-1.13%
Pharma-3.83%
Pharma-3.83%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
RGC Regencell Bioscience HoldingsUS$470.02406.1%
+US$4.9b		8,445.8%PB744.2x
TEVA Teva Pharmaceutical IndustriesUS$17.969.6%
+US$1.8b		6.4%PS1.2x
ZTS ZoetisUS$161.922.4%
+US$1.6b		-3.6%PE28.6x
ELAN Elanco Animal HealthUS$12.8232.8%
+US$1.6b		-24.6%PE17.1x
HRMY Harmony Biosciences HoldingsUS$35.6519.0%
+US$327.9m		18.0%PE13.4x
Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlans & PricingLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & EnterpriseWhat's New
Financial Services GuideTerms and ConditionsPrivacy Policy
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

LLY

US$755.57

Eli Lilly

7D

-8.0%

1Y

-0.3%

ELAN

US$12.82

Elanco Animal Health

7D

32.8%

1Y

-24.6%

Elanco: Deleveraging Takes Time

May 12

RPRX

US$33.35

Royalty Pharma

7D

1.1%

1Y

17.5%

Royalty Pharma: Again, Guidance Raised, Buy Confirmed

May 12

PRGO

US$26.99

Perrigo

7D

6.9%

1Y

-12.4%

author-image

Americas Awards And Supply Chain Savings Will Fuel Future Performance

May 11 Strategic investments in OTC brands and enhanced supply chain efficiencies are poised to improve Perrigo's operating margins and revenue growth.

VTRS

US$8.96

Viatris

7D

4.3%

1Y

-21.1%

PBH

US$88.04

Prestige Consumer Healthcare

7D

6.1%

1Y

24.9%

JNJ

US$154.14

Johnson & Johnson

7D

-0.6%

1Y

1.9%

HRMY

US$35.65

Harmony Biosciences Holdings

7D

19.0%

1Y

18.0%

Results: Harmony Biosciences Holdings, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

May 09
Results: Harmony Biosciences Holdings, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

JAZZ

US$103.58

Jazz Pharmaceuticals

7D

-12.4%

1Y

-8.5%

Earnings Miss: Jazz Pharmaceuticals plc Missed EPS And Analysts Are Revising Their Forecasts

May 09
Earnings Miss: Jazz Pharmaceuticals plc Missed EPS And Analysts Are Revising Their Forecasts

TEVA

US$17.96

Teva Pharmaceutical Industries

7D

9.6%

1Y

6.4%

Teva's Transformation: Why This 'Forgotten Pharma' Could Deliver 30% Upside

May 08

ZTS

US$161.92

Zoetis

7D

2.4%

1Y

-3.6%

MRK

US$80.43

Merck

7D

-2.9%

1Y

-37.8%

BMY

US$48.18

Bristol-Myers Squibb

7D

-3.8%

1Y

6.9%

AXSM

US$110.16

Axsome Therapeutics

7D

-5.4%

1Y

45.6%

Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns

May 06

PFE

US$23.09

Pfizer

7D

-3.3%

1Y

-18.8%

Pfizer's Q1 Update May Mark A Bottom In The Stock

Apr 30

RGC

US$470.02

Regencell Bioscience Holdings

7D

406.1%

1Y

8,445.8%